15. Oktober 2020 – Walder Wyss advised BPI France, Cowen Healthcare Investments, Novo Ventures, OrbiMed and Versant Ventures as lead investors on the USD 110m crossover financing of VectivBio AG.

VectivBio AG is a clinical-stage biotechnology company developing transformational medicines for patients with serious rare diseases.

Proceeds from the financing will be used to support the Phase III program of VectivBio’s lead investigational product, apraglutide, to treat short bowel syndrome (SBS), early commercialization activities and further development of the pipeline through business development initiatives.

The Walder Wyss team included Alexander Gutmans (Partner, Corporate/M&A and Venture Capital) and Karina Tschon (Associate, Corporate/M&A and Venture Capital).